Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
Low doses of the drug FTY720, also called fingolimod, given to mice once a day for three days eliminated an infection by a virus that can cause meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral immune responses in the mice, may be useful against viruses that cause high-level, long-lasting infections in people such as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory University in Atlanta, who led the study, said the researchers plan to assess the effects of the drug on other viruses including the monkey version of the AIDS virus. Altman, whose findings were published in the journal Nature, expressed cautious optimism that the drug might work against certain chronic viral infections in people. "We think it's crucial that we do experiments to check it out," Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant that works to restrain the body's natural defenses. That could be helpful in multiple sclerosis, an autoimmune disease in which the immune system attacks body parts as if they were foreign invaders. But one effect of the drug seems to facilitate the immune response, the researchers said. FTY720 among other things traps white blood cells key soldiers in the immune system's fight against infections in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune response can get primed and started, Altman said. Some viruses replicate themselves at high levels in lymph nodes, including the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called lymphocytic choriomeningitis, which causes chronic infections by escaping immune responses. "In the absence of treatment (with FTY720) we have an exhausted immune response. In the presence of treatment, we regain a robust cellular immune response," Altman said. Swiss drug maker Novartis said in June two multiple sclerosis patients taking FTY720 in clinical trials had problems with infections and one died, but the role of the drug in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the European Union for FTY720 to treat MS, spokeswoman Valerie Tate said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government's National Institutes of Health and was not funded by Novartis.

Ex Output:
MS drug may work against viral infection: study.

Ex Input:
Chaiya, under pressure from health activists and doctors who campaigned to have him sacked, said declaring compulsory licenses on the drugs would save Thailand more than 3 billion baht ($100 million) over the next five years. "The findings have convinced me to go ahead with the CLs since the ministry's policy is to give patients good access to quality drugs at cheap prices," Chaiya said of the review by a panel of Health Ministry officials. The decision is a blow to major pharmaceutical companies which had lobbied hard to reverse the CL policy launched by the previous government appointed after a bloodless 2006 coup. The three drugs are Letrozole, a breast cancer medicine made by Novartis AG, the breast and lung cancer drug Docetaxel by Sanofi-Aventis, and Roche's Erlotinib, used for treating lung, pancreatic and ovarian cancer. A license issued on a leukemia drug, Glivec, was cancelled last month after its maker, Novartis, agreed to supply it free to hundreds of Thai patients. Shortly after a democratically-elected government took power in February, Chaiya ordered the review of a policy he said was a "politically correct decision, but not legally correct". At the time he said the government could afford the full cost of the drugs, if it meant avoiding trade retaliation by the United States, home to some of the world's biggest drug firms. U.S. officials denied there were any plans to impose sanctions on Bangkok, although Thailand was placed on a watch list, meaning Washington believed its respect for patents had weakened. When Chaiya, a businessman with no medical training, fired the Health Ministry's top official negotiating cheaper prices from foreign drug firms, outraged health activists and doctors launched a campaign to remove him. Chaiya said on Monday the ministry would buy cheaper versions of the cancer drugs from generic producers, such as Indian firms which already supply copy-cat HIV-AIDS medicines to Thailand. Under World Trade Organisation rules, countries can issue a compulsory license to make or buy generic versions of patented drugs deemed critical to public health as long as the medicines are meant for domestic use. Former Health Minister Mongkol na Songkhla overrode Merck's AIDS drug Efavirenz in late 2006, arguing that Thailand could not afford patented drugs for a national health plan that covers about 80 percent of the country's 63 million people. A few months later he did the same on a Sanofi-Aventis heart medicine and an AIDS drug made by Abbott Laboratories, which refused to register several new medicines in Thailand. Mongkol, who targeted the four cancer drugs weeks before he left office, has defended the CL policy against major drug firms which accused him of stealing their intellectual property rights. ($1= 30 Baht)

Ex Output:
Thailand will override cancer drug patents.

Ex Input:
Tom Holland, running coach and author of "The Marathon Method," tells his clients that running for 3 miles was horrible for him too, but farther down the road things changed. "It happens for different people at different times and different distances: that runner's high," he said in an interview. Holland calls it a cardiovascular turning point where the run becomes exponentially easier. "There's a point where the run becomes enjoyable," he said. "Whether this happens at 8 or 10 or 12 miles down the road, it will happen," he said. A veteran of 60 marathons, Holland was set to run his ninth New York City Marathon earlier this month, until the 26.2-mile (42.2-kilometer) race was canceled in the wake of Superstorm Sandy. "Over 100,000 people apply to the New York City Marathon each year," he said. "There must be something there that people want." Gregory Chertok, a sports psychologist with the American College of Sports Medicine, said many people are drawn to running because it's an uncomplicated activity. "Put one foot in front of the other and when you work hard, you improve," Chertok said. "Not everything in life is so simple. You could spend 10 years in a ballet studio and not become a ballerina." Few runners enter a marathon to win it, he said. "It's so rare in sporting culture for those who aren't physically or aerobically gifted to feel included in something that's competitive but not exclusive." While it's tough to categorize athletes, Chertok said, long-distance running seems to be appreciated by those who enjoy solitude - or periods of solitude - and are OK with monotony. Chertok differentiates external from internal motivation and said studies show that people who set goals based on intrinsic motivation are more successful. "People run with the initial goal of losing weight or getting fit, which are external goals, but during training they realize they love running, so they end up running for internal reasons," he said. Qualitative evidence for the runner's high suggests that for those prone to its euphoria, it probably contributes to running's addictive quality. "Those that have it swear by it," he said. Most sports medicine practitioners would agree that people are born to be mobile, he said, but not necessarily to run long distances. "Physicians will deter people from running marathon distances, but it's such a powerful allure that it becomes greater than risk of hamstring injury," he said. Richard Finn, spokesman for New York Road Runners, organizers of the New York City Marathon, agrees that long distances do not suit everyone. "Running 26.2 miles is a big, bold brash undertaking," he said. "You've got to put heart, soul, mind, body in it for months. It's like climbing Mount Everest. Not everybody should be doing it." He said a runner is a runner whether you're doing a marathon or a five0kilometer (3.1-mile) race. "We do running 365 days a year, since 1959," Finn said of the New York Road Runners. "Get those sneakers on and run, even on a treadmill. We're not elitist. We think running is good for you." Holland believes running also exposes our weakest link so he urges novices to start slow. "Running is an amazing cheap thing that can make us feel great about ourselves," he said. "But the secret to running is balance. We're born to run but we're not born to run six days a week at the start."

Ex Output:
Long-distance runners lap up miles for the love of it.